Abstract
Gastric cancer is the second most common cause of cancer death worldwide. Recent development of targeted agents provides clinicians with additional systemic treatment options to conventional cytotoxic agents. Predictive markers are undoubtedly important for guiding the appropriate use of targeted and cytotoxic agents. Currently, however, HER2 is the only predictive biomarker validated for gastric cancer. In this review, candidate predictive markers for response to other targeted agents and cytotoxic chemotherapeutic agents are discussed.
Publication types
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Biomarkers*
-
Cytotoxins / administration & dosage
-
ErbB Receptors / antagonists & inhibitors
-
ErbB Receptors / genetics
-
Humans
-
Molecular Targeted Therapy*
-
Receptor, ErbB-2 / antagonists & inhibitors
-
Receptor, ErbB-2 / genetics
-
Receptor, Fibroblast Growth Factor, Type 2 / antagonists & inhibitors
-
Receptor, Fibroblast Growth Factor, Type 2 / genetics
-
Stomach Neoplasms / drug therapy*
-
Stomach Neoplasms / genetics*
-
Stomach Neoplasms / pathology
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
TOR Serine-Threonine Kinases / genetics
Substances
-
Antineoplastic Agents
-
Biomarkers
-
Cytotoxins
-
MTOR protein, human
-
EGFR protein, human
-
ERBB2 protein, human
-
ErbB Receptors
-
FGFR2 protein, human
-
Receptor, ErbB-2
-
Receptor, Fibroblast Growth Factor, Type 2
-
TOR Serine-Threonine Kinases